Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jcjo.2018.03.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hidden face of Parkinson's disease: is it a new autoimmune disease?
Neural Regen Res
December 2024
Department of Pharmacology, Institute of Medical Sciences, College of Medicine, Gyeongsang National University, Jinju, Republic of Korea.
Parkinson's disease is a neurodegenerative disorder marked by the degeneration of dopaminergic neurons and clinical symptoms such as tremors, rigidity, and slowed movements. A key feature of Parkinson's disease is the accumulation of misfolded α-synuclein, forming insoluble Lewy bodies in the substantia nigra pars compacta, which contributes to neurodegeneration. These α-synuclein aggregates may act as autoantigens, leading to T-cell-mediated neuroinflammation and contributing to dopaminergic cell death.
View Article and Find Full Text PDFVitreous Cytokine Profile in an Eye with a Vasoproliferative Tumor.
Retin Cases Brief Rep
December 2024
Department of Ophthalmology, NYU Langone Health, New York, NY.
Purpose: We present a patient with a primary vasoproliferative tumor (VPT) accompanied by vitreous haze and an epiretinal membrane (ERM). We report for the first time the vitreous cytokine profile from an eye with a primary VPT to explore the relationship between intraocular inflammation and these tumors.
Methods: Retrospective chart review of a single patient case.
EAAT2 Activation Regulates Glutamate Excitotoxicity and Reduces Impulsivity in a Rodent Model of Parkinson's Disease.
Mol Neurobiol
December 2024
Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, 19129, USA.
Article Synopsis
- - Parkinson's disease involves the loss of dopamine-producing neurons, leading to disrupted brain circuitry that negatively impacts both cognitive function and decision-making behavior due to elevated glutamate levels.
- - The study investigates GTS467, a drug that activates an important transporter responsible for clearing excess glutamate, hypothesizing it could mitigate cognitive deficits without increasing impulsivity in PD patients.
- - Chronic treatment with GTS467 in rat models showed improved task performance and reduced impulsive actions, alongside beneficial changes in glutamate levels and gene expression related to brain health, supporting its potential as a therapeutic option for PD.
Intraocular use of methotrexate (MTX) for the treatment of proliferative vitreoretinopathy (PVR) in congenital aniridia (CI) and a possible link to aniridia fibrosis syndrome (AFS) treatment.
Am J Ophthalmol Case Rep
December 2024
Department of Ophthalmology at University of Cincinnati, 231 Albert Sabin Way, 5th Floor, Cincinnati, OH, 45267-0527, USA.
Purpose: To present a case of aggressive proliferative vitreoretinopathy (PVR) managed with intraoperative and postoperative intravitreal methotrexate (MTX) in a patient with congenital aniridia (CI).
Observations: A 41-year-old female with a history of CI, living-related conjunctival-kerato-limbal allograft transplantation, and multiple intraocular surgeries presents with tractional retinal detachment (TRD) and aggressive grade C PVR 52 days after a primary 23-gauge pars plana vitrectomy (PPV) with rhegmatogenous retinal detachment repair. She underwent 23-gauge PPV, TRD repair including membrane peeling of pre- and sub-retinal PVR, 5000 centistoke silicone oil exchange, endolaser, and MTX infusion.
Analysis of immunological and biochemical parameters after booster dose vaccination using protein-based and inactivated virus vaccine for safety.
Heliyon
November 2024
Department of Research and Development, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran.
Introduction: Heterologous vaccines enhance the immune response to new variants and allow flexibility in booster administration when the original vaccine is unavailable. Studies show that heterologous boosters can generate comparable or superior antibody responses compared to homologous boosters. Considering rare side effects is essential in evaluating COVID-19 vaccines, especially those associated with ChAdOx1-S (AstraZeneca) and Ad26.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!